BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21051648)

  • 1. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
    Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
    Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
    Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness.
    Nosotti M; Castellani M; Longari V; Chella B; Baisi A; Rosso L; Santambrogio L
    Int Surg; 2008; 93(5):278-83. PubMed ID: 19943430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging.
    Antoch G; Stattaus J; Nemat AT; Marnitz S; Beyer T; Kuehl H; Bockisch A; Debatin JF; Freudenberg LS
    Radiology; 2003 Nov; 229(2):526-33. PubMed ID: 14512512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer.
    Esnaola NF; Lazarides SN; Mentzer SJ; Kuntz KM
    J Clin Oncol; 2002 Jan; 20(1):263-73. PubMed ID: 11773178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion.
    Halpern BS; Schiepers C; Weber WA; Crawford TL; Fueger BJ; Phelps ME; Czernin J
    Chest; 2005 Oct; 128(4):2289-97. PubMed ID: 16236886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.
    Søgaard R; Fischer BM; Mortensen J; Højgaard L; Lassen U
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):802-9. PubMed ID: 21210111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer.
    Lee BE; von Haag D; Lown T; Lau D; Calhoun R; Follette D
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):746-52. PubMed ID: 17320577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
    Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.